Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Resonance Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RHT has not had significant price volatility in the past 3 months.
7 Day Return
AU Medical Equipment
1 Year Return
AU Medical Equipment
Return vs Industry: RHT underperformed the Australian Medical Equipment industry which returned 11.4% over the past year.
Return vs Market: RHT exceeded the Australian Market which returned -5.4% over the past year.
Price Volatility Vs. Market
How volatile is Resonance Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StResonance Health (ASX:RHT) Shareholders Have Enjoyed A Whopping 627% Share Price Gain
4 months ago | Simply Wall StCan We See Significant Insider Ownership On The Resonance Health Limited (ASX:RHT) Share Register?
6 months ago | Simply Wall StAnnouncing: Resonance Health (ASX:RHT) Stock Soared An Exciting 421% In The Last Three Years
Is Resonance Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: RHT (A$0.16) is trading above our estimate of fair value (A$0.02)
Significantly Below Fair Value: RHT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RHT is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.
PE vs Market: RHT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RHT is overvalued based on its PB Ratio (7.2x) compared to the AU Medical Equipment industry average (6.2x).
How is Resonance Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resonance Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Resonance Health's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Resonance Health competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has Resonance Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RHT is currently unprofitable.
Growing Profit Margin: RHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RHT is unprofitable, but has reduced losses over the past 5 years at a rate of 3.7% per year.
Accelerating Growth: Unable to compare RHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RHT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (37.2%).
Return on Equity
High ROE: RHT has a negative Return on Equity (-7.22%), as it is currently unprofitable.
How is Resonance Health's financial position?
Financial Position Analysis
Short Term Liabilities: RHT's short term assets (A$7.8M) exceed its short term liabilities (A$530.9K).
Long Term Liabilities: RHT's short term assets (A$7.8M) exceed its long term liabilities (A$60.1K).
Debt to Equity History and Analysis
Debt Level: RHT is debt free.
Reducing Debt: RHT has not had any debt for past 5 years.
Debt Coverage: RHT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: RHT has no debt, therefore coverage of interest payments is not a concern.
What is Resonance Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Alison Laws has been the Chief Executive Officer at Resonance Health Limited since February 2018. Ms. Laws joined Resonance Health in 2016. She served as Global Account Manager for Resonance Health. Sh ...
CEO Compensation Analysis
Compensation vs Market: Alison's total compensation ($USD216.60K) is about average for companies of similar size in the Australian market ($USD274.65K).
Compensation vs Earnings: Alison's compensation has increased whilst the company is unprofitable.
|Chief Executive Officer||2.67yrs||AU$304.32k||0.0021% |
|CFO & Company Secretary||2.92yrs||AU$322.00k||0.0021% |
|Quality Assurance & Regulatory Affairs Manager||5.33yrs||AU$111.22k||no data|
|Corporate Advisor||3.33yrs||AU$40.00k||no data|
Experienced Management: RHT's management team is considered experienced (3.1 years average tenure).
|Independent Non-Executive Chairman||9.83yrs||AU$483.98k||1.45% |
|Non-Executive Director||2.67yrs||AU$553.98k||0.14% |
|Non-Executive Director||11yrs||AU$463.98k||16.55% |
|Independent Non-Executive Director||3.92yrs||AU$463.98k||0.11% |
Experienced Board: RHT's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.
Resonance Health Limited's company bio, employee growth, exchange listings and data sources
- Name: Resonance Health Limited
- Ticker: RHT
- Exchange: ASX
- Founded: 1987
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$71.092m
- Shares outstanding: 444.32m
- Website: https://www.resonancehealth.com
- Resonance Health Limited
- 141 Burswood Road
- Western Australia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RHT||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Apr 1994|
|RSHT.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Apr 1994|
|RHT||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Apr 1994|
Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship products include FerriScan, a non-invasive liver diagnostic ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/22 10:34|
|End of Day Share Price||2020/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.